Skip to content

BIO-B

BIO-RAD LABORATORIES, INC.

NYSE · Healthcare · Medical - Devices · US

$385.84
+5.69%
Ask drillr

Year over year

Reported trailing growth

Revenue
+1.4%
EBITDA
-22.1%
EBIT
+5.1%
EPS
-29.2%
Free cash flow
+1.6%
Operating cash flow
-7.8%

Forward estimates

Based on analyst estimates

Revenue
+1.3%
EBITDA
+9.3%
EPS
+29.3%

Three-year CAGR

Revenue
-2.7%
EBITDA
+158.4%
EBIT
-17.6%
Net income
+141.2%
EPS
+142.6%
Free cash flow
+67.1%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026